Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

 
Online Download $995
Departmental Site License (one location, 10 users) $1,495
Global Site License $1,990
Published Jul 27, 2016 | 340 Pages | Pub ID: KLI15068137

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025



The pharmaceutical market has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report provides:
  • Corporate Summary
  • Total Company Revenue and Total R&D Spending 2011-2015
  • Break-up of Sales by Region, 2015
  • Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
  • Leading Pharmaceutical Products, 2015 Sales
  • Late Stage Product Pipeline
  • Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
  • Corporate Development Details
The top 25 pharmaceutical companies included in the study are:
  • AbbVie
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Daiichi Sankyo
  • Eli Lilly & Co.
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Novartis
  • Novo Nordisk
  • Otsuka Pharmaceutical
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • TEVA
Despite the new approaches, new technologies and a wealth of new information, drug R&D is still challenged by understanding exactly how drugs will work and why they may fail. Target validation remains a quandary as well. Thus, the hurdle of getting past Phase III trials and launching more NMEs continues. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:
  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • The Role of Contract Research Organizations
The report also looks at market trends and values by therapeutic area, providing information on the following segments:
  • Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
  • Top 5 Neurotherapeutic Companies, 2015 Sales
  • Top 5 Infection Treatment Companies, 2015 Sales
  • Top 5 Oncology Companies, 2015 Sales
  • Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
  • Top 5 Other Drug Companies, 2015 Sales
In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. Data provided include:
  • Global Pharmaceutical Projects in Development by Therapeutic Segment
  • Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market % Change by Therapeutic Segment, 2014-2015
  • Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
  • Top Companies by 2015 Pharmaceutical Sales Growth
  • Global Pharmaceutical Market, Sales Growth by Company, 2014- 2015
  • Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales, 2015 Compared to 2011 and 2013
  • Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
  • Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025—based on late stage development projects evaluated
  • Evaluating Pharmaceutical Company Growth, 2015-2025
  • Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
  • International Population Trend Age 65+
For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals, diagnostics, devices, chemicals, agriculture and animal health. These are areas where many of these companies also compete with significant market shares.

Also, despite an in-depth interview process and complete review of the top 25 pharmaceutical companies' financials and literature, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical sales are not discussed.

This report provides long-term company sales forecasts, which are based on 2015 market conditions. Company forecasts were derived from a combination of pipeline analyses, current product reviews, patent and exclusivity activities, recent merger and alliance impacts, and a number of other factors discovered throughout the writing of this report.

  • $109.00 Included
    •  
      $93.00 Included

    • $93.00 Included
      •   Global Pharmaceutical Projects in Development by Therapeutic Segment

    • $93.00 Included
      •   Figure 1 1 Global Pharmaceutical Market, 2011 2015 and Forecasted 2025

    • $93.00 Included
      •   Leading Pharmaceutical Companies
    •  
      $93.00 Included

  • $93.00 Included

    • $93.00 Included
      •   Figure 2 1 Global Pharmaceutical Market by Therapeutic Area, 2011 2015 and Forecasted 2025

    • $93.00 Included
      •   Top Pharmaceutical Companies, 1 25 by 2015 Pharmaceutical Sales ($ millions)
      •   Figure 2 2 Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales, 2015

    • $93.00 Included
      •   Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates

    • $93.00 Included
      •   Figure 2 3 International Population Trend Age 65+ (Thousands)

  • $547.00 Included
    •  
      $93.00 Included

    • $151.00 Included
      •  
        $93.00 Included

      • $93.00 Included
        •   Phases of Clinical Drug Development

      • $93.00 Included
        •   Top R&D Spenders in the Pharmaceutical Industry - 2013, 2014 and 2015 (in millions)
        •   Figure 3 1 Top 10 R&D Spenders in the Pharmaceutical Industry, 2015 Comparison by Company

      • $93.00 Included
        •   Figure 3 2 Company Pipelines by Total Late Stage Development Projects (Top 25 Companies by Revenues)
        •   Figure 3 3 Cardiovascular/Blood Pipeline Leaders, 2015
        •   Figure 3 4 Neurotherapeutics Pipeline Leaders, 2015
        •   Figure 3 5 Infectious Disease Pipeline Leaders, 2015
        •   Figure 3 6 Oncology Pipeline Leaders, 2015
        •   Figure 3 7 Respiratory/Inflammation Pipeline Leaders, 2015
        •   Figure 3 8 Other Therapy Pipeline Leaders, 2015
    •  
      $93.00 Included
    •  
      $93.00 Included

    • $103.00 Included
      •   Orphan Drug Designations Granted and Approved by the FDA 1983 2016

    • $93.00 Included
      •   Examples of Fast Track Drugs Withdrawn from Market

    • $93.00 Included
      •  
        $93.00 Included

    • $93.00 Included
      •  
        $93.00 Included
    •  
      $93.00 Included

  • $162.00 Included

    • $93.00 Included
      •   Pfizer Corporate Summary

    • $93.00 Included
      •   Pfizer: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

      • $93.00 Included
        •   Figure 4 1 Pfizer: Break up of Total Revenues by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 4 2 Pfizer: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 4 3 Pfizer: Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Pfizer: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Pfizer: Late Stage Product Pipeline
      •   Figure 4 4 Pfizer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $147.00 Included

    • $93.00 Included
      •   Novartis Corporate Summary

    • $93.00 Included
      •   Novartis: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 5 1 Novartis: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 5 2 Novartis: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 5 3 Novartis: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Novartis: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Novartis: Late Stage Product Pipeline
      •   Figure 5 4 Novartis: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $167.00 Included

    • $93.00 Included
      •   Roche Corporate Summary

    • $93.00 Included
      •   Roche: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 6 1 Roche: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 6 2 Roche: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 6 3 Roche: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Roche: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Roche: Late Stage Product Pipeline
      •   Figure 6 4 Roche: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $122.00 Included

    • $93.00 Included
      •   Merck Corporate Summary

    • $93.00 Included
      •   Merck: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 7 1 Merck: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 7 2 Merck: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 7 3 Merck: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Merck: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Merck: Late Stage Product Pipeline
      •   Figure 7 4 Merck: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $123.00 Included

    • $93.00 Included
      •   Sanofi Corporate Summary

    • $93.00 Included
      •   Sanofi Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 8 1 Sanofi: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 8 2 Sanofi: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 8 3 Sanofi: Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Sanofi: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Sanofi Late Stage Product Pipeline
      •   Figure 8 4 Sanofi: Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $101.00 Included

    • $93.00 Included
      •   Gilead Sciences Corporate Summary

    • $93.00 Included
      •   Gilead Sciences: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 9 1 Gilead Sciences: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 9 2 Gilead Sciences: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 9 3 Gilead Sciences: Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Gilead Sciences: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Gilead Sciences: Late Stage Product Pipeline
      •   Figure 9 4 Gilead Sciences: Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Gilead Sciences: Highlighted Corporate Developments

  • $152.00 Included

    • $93.00 Included
      •   Johnson & Johnson Corporate Summary

    • $93.00 Included
      •   Johnson & Johnson: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 10 1 Johnson & Johnson: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 10 2 Johnson & Johnson: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 10 3 Johnson & Johnson: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Johnson & Johnson: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Johnson & Johnson: Late Stage Product Pipeline
      •   Figure 10 4 Johnson & Johnson: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $122.00 Included

    • $93.00 Included
      •   GlaxoSmithKline Corporate Summary

    • $93.00 Included
      •   GlaxoSmithKline: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 11 1 GlaxoSmithKline: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 11 2 GlaxoSmithKline: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 11 3 GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   GlaxoSmithKline: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   GlaxoSmithKline: Late Stage Product Pipeline
      •   Figure 11 4 GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $138.00 Included

    • $93.00 Included
      •   AstraZeneca Corporate Summary

    • $93.00 Included
      •   AstraZeneca: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 12 1 AstraZeneca: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 12 2 AstraZeneca: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 12 3 AstraZeneca: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   AstraZeneca: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   AstraZeneca: Late Stage Product Pipeline
      •   Figure 12 4 AstraZeneca: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $93.00 Included

    • $93.00 Included
      •   AbbVie Corporate Summary

    • $93.00 Included
      •   AbbVie: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 13 1 AbbVie: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 13 2 AbbVie: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   AbbVie: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   AbbVie: Late Stage Product Pipeline
      •   Figure 13 3 AbbVie: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $117.00 Included

    • $93.00 Included
      •   Amgen Corporate Summary

    • $93.00 Included
      •   Amgen: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 14 1 Amgen: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 14 2 Amgen: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 14 3 Amgen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Amgen: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Amgen: Late Stage Product Pipeline
      •   Figure 14 4 Amgen: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $125.00 Included

    • $93.00 Included
      •   Teva Pharmaceutical Corporate Summary

    • $93.00 Included
      •   Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 15 1 Teva Pharmaceutical: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 15 2 Teva Pharmaceutical: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 15 3 Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Teva Pharmaceutical: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Teva Pharmaceutical: Late Stage Product Pipeline Brand Development
      •   Figure 15 4 Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics) Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $112.00 Included

    • $93.00 Included
      •   Eli Lilly Corporate Summary

    • $93.00 Included
      •   Eli Lilly's Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 16 1 Eli Lilly & Co.: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 16 2 Eli Lilly & Co.: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 16 3 Eli Lilly & Co.: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Eli Lilly & Co.: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Eli Lilly: Late Stage Product Pipeline
      •   Figure 16 4 Eli Lilly & Co.: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $125.00 Included

    • $93.00 Included
      •   Bristol Myers Squibb Corporate Summary

    • $93.00 Included
      •   Bristol Myers Squibb's Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 17 1 Bristol Myers Squibb: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 17 2 Bristol Myers Squibb: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025,($millions)
      •   Figure 17 3 Bristol Myers Squibb: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Bristol Myers Squibb: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Bristol Myers Squibb: Late Stage Product Pipeline

    • $93.00 Included
      •   Bristol Myers Squibb Highlighted Corporate Developments

  • $93.00 Included

    • $93.00 Included
      •   Novo Nordisk Corporate Summary

    • $93.00 Included
      •   Novo Nordisk: Total Company Revenue and Total R&D Spending 2011 2015 (millions)

    • $93.00 Included
      •   Figure 18 1 Novo Nordisk: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 18 2 Novo Nordisk: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 18 3 Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Novo Nordisk: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Novo Nordisk: Late Stage Product Pipeline
      •   Figure 18 4 Novo Nordisk: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $97.00 Included

    • $93.00 Included
      •   Bayer Corporate Summary

    • $93.00 Included
      •   Bayer's Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 19 1 Bayer: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 19 2 Bayer: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 19 3 Bayer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Bayer: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Bayer: Late Stage Product Pipeline
      •   Figure 19 4 Bayer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $132.00 Included

    • $93.00 Included
      •   Takeda Corporate Summary

    • $93.00 Included
      •   Takeda's Total Company Revenue* and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 20 1 Takeda: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 20 2 Takeda: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 20 3 Takeda: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Takeda: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Takeda Pharmaceutical: Late Stage Product Pipeline
      •   Figure 20 4 Takeda: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $93.00 Included

    • $93.00 Included
      •   Boehringer Ingelheim Corporate Summary

    • $93.00 Included
      •   Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 21 1 Boehringer Ingelheim: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 21 2 Boehringer Ingelheim: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 21 3 Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Boehringer Ingelheim: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Boehringer Ingelheim: Late Stage Product Pipeline
      •   Figure 21 4 Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $93.00 Included

    • $93.00 Included
      •   Allergan plc Corporate Summary

    • $93.00 Included
      •   Allergan: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 22 1 Allergan: Pharmaceutical Business Performance, 2014 2015 and Forecasted 2025 ($millions)
      •   Figure 22 2 Allergan: Pharmaceutical Segment Sales 2014 2015 and Forecasted 2025

    • $93.00 Included
      •   Allergan: Late Stage Product Pipeline Brand Development

    • $93.00 Included
      •   Allergan: Highlighted Corporate Developments

  • $95.00 Included

    • $93.00 Included
      •   Astellas Corporate Summary

    • $93.00 Included
      •   Astellas: Total Company Revenue and Total R&D Spending 2011 2015 (millions)

    • $93.00 Included
      •   Figure 23 1 Astellas: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 23 2 Astellas: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 23 3 Astellas: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Astellas: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Astellas: Late Stage Product Pipeline
      •   Figure 23 4 Astellas: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $93.00 Included

    • $93.00 Included
      •   Mylan Corporate Summary

    • $93.00 Included
      •   Mylan: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 24 1 Mylan: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 24 2 Mylan: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 24 3 Mylan: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
    •  
      $93.00 Included

    • $93.00 Included
      •   Corporate Development Details

  • $93.00 Included

    • $93.00 Included
      •   Biogen Corporate Summary

    • $93.00 Included
      •   Biogen: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 25 1 Biogen: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 25 2 Biogen: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 25 3 Biogen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Biogen: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Biogen: Late Stage Product Pipeline
      •   Figure 25 4 Biogen: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011 and 2013

    • $93.00 Included
      •   Biogen: Highlighted Corporate Developments

  • $93.00 Included

    • $93.00 Included
      •   Celgene Corporate Summary

    • $93.00 Included
      •   Celgene: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 26 1 Celgene: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 26 2 Celgene: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 26 3 Celgene: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Celgene: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Celgene: Late Stage Product Pipeline
      •   Figure 26 4 Celgene: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Celgene: Corporate Development Details

  • $104.00 Included

    • $93.00 Included
      •   Otsuka Corporate Summary

    • $93.00 Included
      •   Otsuka Holdings: Total Company Revenue and Total R&D Spending 2011 2015 (Millions)

    • $93.00 Included
      •   Figure 27 1 Otsuka Holdings: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 27 2 Otsuka Holdings: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2023 ($millions)
      •   Figure 27 3 Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Otsuka Holdings: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Otsuka Holdings: Late Stage Product Pipeline
      •   Figure 27 4 Otsuka Holdings: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $107.00 Included

    • $93.00 Included
      •   Daiichi Sankyo Corporate Summary

    • $93.00 Included
      •   Daiichi Sankyo: Total Company Revenue and Total R&D Spending 2011 2015 (millions)

    • $93.00 Included
      •   Figure 28 1 Daiichi Sankyo: Break up of Sales by Region, 2015 (in percent)

    • $93.00 Included
      •   Figure 28 2 Daiichi Sankyo: Pharmaceutical Business Performance, 2011 2015 and Forecasted 2025 ($millions)
      •   Figure 28 3 Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025

      • $93.00 Included
        •   Daiichi Sankyo: Leading Pharmaceutical Products, 2015 Sales (millions)

    • $93.00 Included
      •   Daiichi Sankyo: Late Stage Product Pipeline
      •   Figure 28 4 Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015

    • $93.00 Included
      •   Highlighted Corporate Developments

  • $391.00 Included

    • $93.00 Included
      •   Global Pharmaceutical Market, 2011 2015 and Forecasted 2025($ in billions)
      •   Figure 29 1 Global Pharmaceutical Market, 2011 2015 and Forecasted 2025

    • $149.00 Included
      •   Figure 29 2 Global Pharmaceutical Market by Therapeutic Area, 2011 2015 and Forecasted 2025

      • $93.00 Included
        •   Figure 29 3 Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales

      • $93.00 Included
        •   Figure 29 4 Top 5 Neurotherapeutic Companies, 2015 Sales

      • $93.00 Included
        •   Figure 29 5 Top 5 Infection Treatment Companies, 2015 Sales

      • $93.00 Included
        •   Figure 29 6 Top 5 Oncology Companies, 2015 Sales

      • $93.00 Included
        •   Figure 29 6 Top 5 Respiratory and Inflammation Product Companies, 2015 Sales

      • $93.00 Included
        •   Figure 29 7 Top 5 Other Drug Companies, 2015 Sales

    • $93.00 Included
      •   Figure 29 8 Global Pharmaceutical Market % Change by Therapeutic Segment, 2014 2015

      • $93.00 Included
        •   Top Companies by 2015 Pharmaceutical Sales Growth ($ millions)
        •   Figure 29 9 Global Pharmaceutical Market, Sales Growth by Company, 2014 2015

    • $93.00 Included
      •   Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales 2015 Compared to 2011 and 2013 (millions)
      •   Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues (billions)

    • $93.00 Included
      •   Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025-based on late stage development projects evaluated ($ in billions)
      •   Figure 29 11 Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025-based on late stage development projects evaluated

    • $93.00 Included
      •   Evaluating Pharmaceutical Company Growth, 2015 2025 ($ millions)

In this report, {{keyword[keywordTextProperty]}} appears {{keyword[keywordCountProperty]}} times. {{searchResults.STATRESULT.SUMMARY.KW[keywordTextProperty]}} appears {{searchResults.STATRESULT.SUMMARY.KW[keywordCountProperty]}} times.

We were unable to search inside this report.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.